Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

20.61 -0.54 (-2.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 644,392
Open 21.21
Bid (Size) 15.00 (1)
Ask (Size) 29.20 (1)
Prev. Close 21.15
Today's Range 20.20 - 21.50
52wk Range 20.20 - 62.16
Shares Outstanding 58,951,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff
 
Via Benzinga
7 Analysts Have This to Say About Agios Pharmaceuticals
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter: 
Via Benzinga

Performance

YTD
-40.79%
-40.79%
1 Month
-20.85%
-20.85%
3 Month
-30.04%
-30.04%
6 Month
-46.76%
-46.76%
1 Year
-62.60%
-62.60%

More News

Read More
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Agios Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
Analyst Ratings For Agios Pharmaceuticals
Via Benzinga
What 4 Analyst Ratings Have To Say About Agios Pharmaceuticals
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Via Benzinga
FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Via Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
Via InvestorPlace
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Via Talk Markets
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
Via Benzinga
Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
Via Benzinga
Exposures Product Safety
This Company Says It's One Step Closer to Transforming Cancer Treatment with its Latest Groundbreaking Immunotherapy
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021
Via Benzinga
Agios Pharmaceuticals, inc (AGIO) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Via Benzinga
Topics Retirement
Exposures Pension
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.